BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors

Reuters · Feb 23, 2021 20:23

Feb 23 (Reuters) - Oncolytics Biotech Inc ONC.TO :

* ONCOLYTICS BIOTECH REPORTS PRECLINICAL DATA DEMONSTRATING SYNERGISTIC ANTI-CANCER ACTIVITY OF PELAREOREP COMBINED WITH CAR T CELL THERAPY IN SOLID TUMORS

* ONCOLYTICS BIOTECH INC - MAYO CLINIC SHOWS PELAREOREP VASTLY IMPROVED PERSISTENCE AND EFFICACY OF CAR T CELL THERAPY LEADING TO CURES IN MODEL

* ONCOLYTICS BIOTECH INC - PELAREOREP&aposS SYNERGISTIC EFFECTS WITH CAR T THERAPY APPEAR TO BE SPECIFIC AND WERE NOT OBSERVED WITH ONCOLYTIC VIRUS VSV

* ONCOLYTICS BIOTECH INC - RESULTS DEMONSTRATE POTENTIAL OF PELAREOREP TO BROADEN APPLICABILITY OF CAR T CELLS TO SOLID TUMORS

Source text for Eikon: Further company coverage:

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors

Risk Disclaimer